文献速递糖尿病

2型糖尿病血糖控制不佳者换用iGlarLixi与继续GLP-1受体激动剂的随机对照研究

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
PubMed 文献 · Diabetes Care · 2019-09-17

LixiLan-G是一项随机、开放标签、26周试验,纳入HbA1c 7-9%且已用最大耐受剂量GLP-1受体激动剂(日制剂或周制剂)联合口服降糖药的2型糖尿病患者,比较换用iGlarLixi与继续原GLP-1受体激动剂治疗。结果显示iGlarLixi组HbA1c降幅更大,达标率更高,但恶心、呕吐及有症状低血糖事件相对更多。

要点

  • 对最大耐受剂量GLP-1受体激动剂联合口服药控制不佳者,换用iGlarLixi可进一步改善血糖。
  • iGlarLixi组HbA1c<7%达标率62% vs 26%,低血糖与胃肠道事件总体较低但高于继续原治疗。
  • 换药决策需权衡血糖获益与恶心、呕吐及低血糖风险。

核心结论

  • 在最大耐受剂量GLP-1受体激动剂联合口服降糖药控制不佳的2型糖尿病患者中,换用iGlarLixi较继续原GLP-1受体激动剂治疗可改善血糖控制。

研究设计与样本

  • LixiLan-G为随机、开放标签、26周试验,比较换用iGlarLixi与继续原GLP-1受体激动剂治疗。
  • 纳入HbA1c 7-9%(53-75 mmol/mol)的2型糖尿病患者,基线使用最大耐受剂量GLP-1受体激动剂(60%为日制剂,40%为周制剂)联合二甲双胍±吡格列酮±SGLT2抑制剂。
  • iGlarLixi组与继续GLP-1受体激动剂组各257例。

主要发现

  • 26周时iGlarLixi组HbA1c由基线7.8%(62 mmol/mol)降至6.7%(50 mmol/mol),对照组降至7.4%(57 mmol/mol),最小二乘均值差-0.6%(P<0.0001)。
  • iGlarLixi组HbA1c<7%(53 mmol/mol)达标率62%,对照组26%(P<0.0001)。
  • iGlarLixi组达到HbA1c<7%且无文档化有症状低血糖(<54 mg/dL)复合终点的患者更多。
  • 恶心、呕吐发生率及每患者年文档化有症状低血糖事件数在两组总体较低,但iGlarLixi组高于继续GLP-1受体激动剂组。

关键数值与推荐

  • HbA1c入组范围7-9%(53-75 mmol/mol)。
  • 26周HbA1c降幅组间最小二乘均值差-0.6%(P<0.0001)。
  • HbA1c<7%(53 mmol/mol)达标率62% vs 26%(P<0.0001)。
  • 低血糖定义:文档化有症状低血糖为<54 mg/dL。

临床怎么用

  • 对已用最大耐受剂量GLP-1受体激动剂联合口服药但HbA1c仍不达标者,可考虑换用iGlarLixi以进一步降低HbA1c并提高达标率。
  • 换药时应关注恶心、呕吐及有症状低血糖风险,并加强监测与剂量滴定。

局限性

  • 为随机、开放标签设计,随访26周,非双盲。
  • 恶心、呕吐及低血糖事件总体较低但iGlarLixi组更多,需在个体化决策中权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Fixed-ratio combinations of basal insulin plus glucagon-like peptide 1 receptor agonist (GLP-1 RA) allow concomitant administration of two proven complementary injectable therapies for type 2 diabetes. This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or weekly GLP-1 RA therapy. RESEARCH DESIGN AND METHODS: LixiLan-G, a randomized, open-label, 26-week trial, compared switching to iGlarLixi versus continuing prior GLP-1 RA in patients with type 2 diabetes and HbA1c 7-9% (53-75 mmol/mol) taking maximum tolerated doses of a GLP-1 RA daily (60% on liraglutide once daily or exenatide twice daily) or weekly (40% on dulaglutide, exenatide extended release, or albiglutide) with metformin with or without pioglitazone and with or without sodium-glucose cotransporter 2 inhibitors. Adherence to randomized treatment was closely monitored throughout the study. RESULTS: iGlarLixi (n = 257) reduced HbA1c more than continued GLP-1 RA therapy (n = 257) from a baseline 7.8% (62 mmol/mol) in both to 6.7% (50 mmol/mol) and 7.4% (57 mmol/mol), respectively, at 26 weeks (least squares mean difference -0.6%; P < 0.0001). More iGlarLixi patients achieved HbA1c <7% (53 mmol/mol) (62% vs. 26%; P < 0.0001) and the composite of HbA1c <7% without documented symptomatic hypoglycemia (<54 mg/dL). Nausea and vomiting rates as well as numbers of documented symptomatic hypoglycemia events per patient-year were generally low but greater with iGlarLixi versus continued GLP-1 RA therapy. CONCLUSIONS: Switching to iGlarLixi improves glucose control for patients with type 2 diabetes insufficiently controlled on a maximum tolerated dose of a GLP-1 RA plus oral antihyperglycemic agents.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Blonde L, Rosenstock J, Del Prato S, et al. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes Care. 2019. PMID: 31530665. doi:10.2337/dc19-1357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。